Preventing central nervous system metastases in non-small cell lung cancer

References

• Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int. 2013;4(Suppl 4):192–202.
   Google Scholar
• Metro G, Chiari R, Ricciuti B, et al. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother. 2015;16:2601–2613.
   PubMed Web of Science ®Google Scholar
• Takei H, Rouah E, Ishida Y. Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications. Brain Tumor Pathol. 2016;33:1–11.
   PubMed Web of Science ®Google Scholar
• Robnett TJ, Machtay M, Stevenson JP, et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 2001;19(5):1344–1349.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827–831.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stanley K, Petrovich Z, et al. Cranial irradiation in cancer of the lung of all cell types. JAMA. 1981;245:469–472.
   PubMed Web of Science ®Google Scholar
• Mira JG, Miller TP, Crowley JJ, et al. Chest irradiation vs. chest irradiation plus chemotherapy with or without prophylactic brain radiotherapy in localized non- small lung cancer: a southwest oncology group study. Int J Radiat Oncol Biol Phys. 1990;19:145.
   Google Scholar
• Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol. 1984;2(3):253–259.
   PubMed Web of Science ®Google Scholar
• Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1991;21(3):637–643.
   PubMed Web of Science ®Google Scholar
• Pöttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol. 2007;25(31):4987–4992.
   PubMed Web of Science ®Google Scholar
• Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29(3):272–278.
   PubMed Web of Science ®Google Scholar
• Li N, Zeng ZF, Wang SY, et al. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol. 2015;26(3):504–509.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study. J Clin Oncol. 2018;36(23):2366–2377.
   PubMed Web of Science ®Google Scholar
• Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279–286.
   PubMed Web of Science ®Google Scholar
• Xie SS, Li M, Zhou CC, et al. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014;9(7):e103431.
   PubMed Web of Science ®Google Scholar
• Jacobs RH, Awan A, Bitran JD, et al. Prophylactic cranial irradiation in adenocarcinoma of the lung a possible role. Cancer. 1987;59(12):2016–2019.
   PubMed Web of Science ®Google Scholar
• Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol. 1999;17(9):2700.
   PubMed Web of Science ®Google Scholar
• Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III N0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol. 1989;40(4):266–274.
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon J, Sherman D, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIa non-small- cell carcinoma of the lung: report of a cancer and leukemia group B phase II study. J Clin Oncol. 1992;10(8):1237–1244.
   PubMed Web of Science ®Google Scholar
• Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIa (n2) and IIIb non-small-cell lung cancer: mature results of southwest oncology group phase II study 8805. J Clin Oncol. 1995;13(8):1880–1892.
   PubMed Web of Science ®Google Scholar
• Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:77–84.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Gielda BT, Herskovic AM, et al. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol. 2010;2010:198208.
   PubMedGoogle Scholar
• Precival C, Landy M, Poole C, et al. The role of prophylactic cranial irradiation for non-small cell lung cancer. Anticancer Res. 2018;38:7–14.
   PubMed Web of Science ®Google Scholar
• Gawkowska-Suwińska M, Blamek S, Heyda A, et al. Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer–results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes). Rep Pract Oncol Radiother. 2014;19(6):361–368.
   PubMedGoogle Scholar
• Boggs DH, Robins HI, Langer CJ, et al. Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014;15(6):433–440.
   PubMed Web of Science ®Google Scholar
• Ortazur W, Hanna N, Pennella E, et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13:24–30.
   PubMed Web of Science ®Google Scholar
• Monaco SE, Nikiforova MN, Cieply K, et al. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Path. 2010;41:94–102.
   PubMed Web of Science ®Google Scholar
• Villalva C, Duranton-Tanneur V, Guilloteau K, et al. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med. 2013;2:296–304.
   PubMed Web of Science ®Google Scholar
• Nicoś M, Krawczyk P, Jarosz B, et al. Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer. Brain Pathol. 2018;28:295–297.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415–1426.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006.
   PubMed Web of Science ®Google Scholar
• Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer. 2016;138:2549–2561.
   PubMed Web of Science ®Google Scholar
• Bai H, Xiong L, Han B. The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. Onco Targets Ther. 2017;10:2335–2340.
   PubMed Web of Science ®Google Scholar
• Fan Y, Xu X, Xie C EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. Onco Targets Ther. 2014; 7: 2075–2084.
   PubMed Web of Science ®Google Scholar
• Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16:e510–521.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873–5882.
   PubMed Web of Science ®Google Scholar
• Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406–4414.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70:399–405.
   PubMed Web of Science ®Google Scholar
• Li MX, He H, Ruan ZH, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer. 2017;17(1):245.
   PubMedGoogle Scholar
• Yang JCH, Wu YL, Hirsh V, et al. Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. J Thor Oncol. 2018;13(4, suppl.):84–85.
   Web of Science ®Google Scholar
• Ma X, Zhu H, Guo H, et al. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget. 2016;7(49):81906–81917.
   PubMedGoogle Scholar
• Shi W, Dicker AP. (2016) CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol. 2016;34:107–109.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886.
   PubMed Web of Science ®Google Scholar
• Nishio M, Nakagawa K, Mitsudomi T, et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2018;121:37–40.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-Positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Show T, Barlesi F, et al. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018;118(1):38–42.
   PubMed Web of Science ®Google Scholar
• Cho JH. Immunotherapy for non-small-cell lung cancer: current status and future obstacles. Immune Netw. 2017;17(6):378–391.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
   PubMed Web of Science ®Google Scholar
• Rossi S, Finocchiaro G, Marchetti S, et al. Checkpoint inhibitors: ‘raising the bar’ also in brain metastases from non-small-cell lung cancer? Immunotherapy. 2018. DOI:10.2217/imt-2017-0151.
   Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases. Lancet Oncol. 2016;17(7):976–983.
   PubMed Web of Science ®Google Scholar